A window of opportunity study for investigating DTP disease with preoperative brigatinib in resectable ALK NSCLC (NCT05361564) is due to start recruitment and will provide an excellent opportunity to investigate the molecular underpinnings of tumor persistence in ALK-treated patient’s resection specimens after neoadjuvant therapy. This evidence concerns the gene ALK and neoplasm.